Perspective Therapeutics (CATX) updates corporate presentation with preliminary 2025 data

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. filed an 8-K to note that it has updated its corporate presentation and posted it on its website. The presentation includes preliminary estimated and projected financial information, including estimated cash, cash equivalents and short-term investments as of December 31, 2025.

The company emphasizes that these figures are unaudited and have not been reviewed or compiled by its independent registered public accounting firm, WithumSmith+Brown, PC, which provides no assurance on the data. Actual results for the year ended December 31, 2025 may differ once closing procedures and final adjustments are completed.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000728387false00007283872026-02-022026-02-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 02, 2026

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CATX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 2, 2026, Perspective Therapeutics, Inc. (the "Company") updated its corporate presentation (the "Presentation"). The Presentation contains certain estimated and projected financial information, including the Company’s estimated cash, cash equivalents and short-term investments as of December 31, 2025. The estimated and projected financial information included in the Presentation is preliminary and has not been audited, reviewed or compiled by the Company’s independent registered public accounting firm, WithumSmith+Brown, PC (“Withum”), and Withum has not performed any procedures with respect to the preliminary financial data. Accordingly, Withum does not express an opinion or any other form of assurance with respect thereto.

The Company’s actual results as of December 31, 2025 may differ from the preliminary financial data due to the completion of the Company’s closing procedures with respect to the year ended December 31, 2025, final adjustments and other developments that may arise between now and the time the financial results for the fiscal year are finalized.

Item 8.01 Other Events.

On February 2, 2026, the Company posted the Presentation to its website. A copy of the Presentation is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	February 2, 2026	By:	/s/ Joel Sendek
			Joel Sendek Chief Financial Officer

FAQ

What did Perspective Therapeutics (CATX) disclose in its latest 8-K?

Perspective Therapeutics disclosed that it updated its corporate presentation and posted it on its website. The presentation includes preliminary estimated and projected financial information, including estimated cash, cash equivalents and short-term investments as of December 31, 2025.

Does the Perspective Therapeutics (CATX) presentation include preliminary financial data?

Yes. The updated corporate presentation includes preliminary estimated and projected financial information, such as estimated cash, cash equivalents and short-term investments as of December 31, 2025. This information is subject to change as year-end closing procedures and final adjustments are completed.

Has Perspective Therapeutics’ preliminary financial information been audited or reviewed?

No. The preliminary financial information in the corporate presentation has not been audited, reviewed or compiled by WithumSmith+Brown, PC. The firm has not performed procedures on the data and does not express an opinion or any other form of assurance regarding it.

Why might Perspective Therapeutics’ actual 2025 results differ from the estimates?

Actual results may differ from the preliminary estimates because the company still must complete its closing procedures for the year ended December 31, 2025. Final adjustments and other developments could change the financial results before they are fully finalized.

Where can investors access the new Perspective Therapeutics (CATX) corporate presentation?

The company states that the updated corporate presentation has been posted to its website. A copy is also included as Exhibit 99.1 to the 8-K filing and is incorporated by reference into the Other Events section.

What exhibit numbers are included in the Perspective Therapeutics 8-K filing?

The filing lists Exhibit 99.1 as the corporate presentation and Exhibit 104 as the cover page interactive data file. The interactive data is embedded within the Inline XBRL document accompanying the 8-K.